Robert Díaz Beveridge

Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial

Alessandro Gronchi, Stefano Ferrari, Vittorio Quagliuolo et al. · The Lancet Oncology · 2017 · 489 citations

Medicine, Oncology, Surgery +17

Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups

Alessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo et al. · Journal of Clinical Oncology · 2020 · 261 citations · Full text

Medicine, Oncology, Pharmacology +17

Neoadjuvant chemotherapy in high‐risk soft tissue sarcomas: A Sarculator‐based risk stratification analysis of the ISG‐STS 1001 randomized trial

Sandro Pasquali, Emanuela Palmerini, Vittorio Quagliuolo et al. · Cancer · 2021 · 101 citations · Full text

Medicine, Oncology, Surgery +16

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

Angus Dalgleish, Justin Stebbing, Douglas JA Adamson et al. · British Journal of Cancer · 2016 · 75 citations · Full text

Medicine, Oncology, Pharmacology +13

SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016)

Marta Martín-Richard, Robert Díaz Beveridge, Virginia Arrazubi et al. · Clinical & Translational Oncology · 2016 · 29 citations · Full text

Medicine, Oncology, Surgery +17